Combination therapy with the BRD4 inhibitor JQ1 or OTX015 and Panobinostat synergistically reduces the expression of oncogenes, such as MYC, MYCN and LIN28B; suppresses proliferation and induces apoptosis in MYCN gene-amplified neuroblastoma, medulloblastoma and diffuse intrinsic pontine glioma cells; and significantly suppresses neuroblastoma and medulloblastoma tumor progression in mouse models [21, 49, 50]. Here, BRD4 is linked to neoplasm.